CYTK Stock Overview
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Cytokinetics, Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$66.82 |
| 52 Week High | US$110.25 |
| 52 Week Low | US$25.98 |
| Beta | 0.68 |
| 1 Month Change | -2.78% |
| 3 Month Change | -19.41% |
| 1 Year Change | 79.91% |
| 3 Year Change | 147.94% |
| 5 Year Change | 703.13% |
| Change since IPO | -30.83% |
Recent News & Updates
Cytokinetics, Incorporated: Buyout Speculation Persists
Apr 01Cytokinetics: CEO Talks Down Buyout Prospects
Mar 16Recent updates
Cytokinetics, Incorporated: Buyout Speculation Persists
Apr 01Cytokinetics: CEO Talks Down Buyout Prospects
Mar 16Cytokinetics Steps Up As Prime Target After Aficamten's HCM Triumph (Rating Upgrade)
Jan 12An Intrinsic Calculation For Cytokinetics, Incorporated (NASDAQ:CYTK) Suggests It's 37% Undervalued
Oct 05
Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week
May 07Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week
Mar 03Cytokinetics, Incorporated's (NASDAQ:CYTK) Intrinsic Value Is Potentially 100% Above Its Share Price
Jan 20Newsflash: Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Have Been Trimming Their Revenue Forecasts
Dec 15Cytokinetics: Surprise Adcomm For Omecamtiv Causing Concern
Oct 17Cytokinetics gets monitoring panel's nod to continue phase 3 trial of ALS drug reldesemtiv
Oct 10Cytokinetics (NASDAQ:CYTK) Has Debt But No Earnings; Should You Worry?
Aug 23Shareholder Returns
| CYTK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.6% | 1.0% | 1.2% |
| 1Y | 79.9% | 0.7% | 24.9% |
Return vs Industry: CYTK exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: CYTK exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| CYTK volatility | |
|---|---|
| CYTK Average Weekly Movement | 6.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CYTK's share price has been volatile over the past 3 months.
Volatility Over Time: CYTK's weekly volatility has decreased from 14% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 423 | Robert Blum | www.cytokinetics.com |
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.
Cytokinetics, Incorporated Fundamentals Summary
| CYTK fundamental statistics | |
|---|---|
| Market cap | US$6.87b |
| Earnings (TTM) | -US$526.24m |
| Revenue (TTM) | US$7.53m |
929.7x
P/S Ratio-13.3x
P/E RatioIs CYTK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYTK income statement (TTM) | |
|---|---|
| Revenue | US$7.53m |
| Cost of Revenue | US$330.12m |
| Gross Profit | -US$322.59m |
| Other Expenses | US$203.65m |
| Earnings | -US$526.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.02 |
| Gross Margin | -4,284.10% |
| Net Profit Margin | -6,988.63% |
| Debt/Equity Ratio | -159.8% |
How did CYTK perform over the long term?
See historical performance and comparison